fda glp 1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA moves to remove GLP-1
Description
Paulescu published his results the following year and then took out a Romanian patent on his technique in April 1922
Studies involving adult IIH patients treated with GLP-1 RAs and reporting relevant clinical outcomes were included
One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
6 For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies
They must be prescribed and monitored by a qualified healthcare professional
